Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline
CompanyDeals

Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline

Yanyin Tech and CirCode Biomed Forge Three-Year RNA Drug Development Partnership
CompanyDeals

Yanyin Tech and CirCode Biomed Forge Three-Year RNA Drug Development Partnership

China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases
CompanyDeals

China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases

Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications
CompanyDeals

Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications

Pacific Shuanglin's Controlling Stake Transferred to CNBG in RMB 4.7B Deal
CompanyDeals

Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal

Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology
CompanyDeals

Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology

Yanyin Tech and ChangJiang Pharma Partner to Advance AI in Drug Development
CompanyDeals

Yanyin Tech and ChangJiang Pharma Partner to Advance AI in Drug Development

Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China
Drug

Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China

Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC
CompanyDrug

Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC

Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies
CompanyDeals

Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies

Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine
CompanyDeals

Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine

Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease
CompanyDrug

Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease